More from Renaissance Capital
Referenced Stocks

Stemline Therapeutics postpones IPO

By Renaissance Capital,  August 07, 2012, 09:55:46 AM EDT

Stemline Therapeutics, a biotech developing treatments that target cancer stem cells and tumor bulk, postponed its IPO on Tuesday. The New York, NY-based company had been planning to raise $42 million at a price range of $11 to $13. RBC Capital Markets, Oppenheimer & Co. were set to be the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.


This article appears in: News Headlines, IPOs

Referenced Stocks: STML



Latest News Video

Preschool Reportedly Bans Imaginary Superhero Play
Preschool Reportedly Bans Imaginary...
4.8 Million Seniors Are Food Insecure
4.8 Million Seniors Are Food Insecu...


Sign-in
Existing NASDAQ.com member? Log in here.

By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

From Our Trusted News Source





Most Active by Volume:

Company Last Sale Change Net / %
BAC $ 13.30 0.01  0.08%
HPQ $ 24.082 2.85  13.43%
MU $ 11.36 0.44  4.03%
MSFT $ 34.29 0.32  0.92%
F $ 14.86 0.11  0.73%
C $ 50.47 0.53  1.04%
SIRI $ 3.505 0.03  0.85%
QQQ $ 73.52 0.10  0.13%